Issued 2026-08-13 at $4.01 · now $4.09 (2026-08-13, +2.0% since)
Based on its own history, a month from the 2026-08-13 close, ALVO has typically landed between $3.01 and $5.06 — a range of −25.1% to +26.2% from the issuance price $4.01.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,022 overlapping 1 month windows · 2022-06-16 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($4.01) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where ALVO has typically landed a month from the 2026-08-13 close of $4.01 — the range is history, not a prediction.
- now $4.09 (+2.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $3.93 (-2.0%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $3.54–$4.31
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $3.01–$5.06
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-10-06 | −43.7% | −43.7% | +4.7% |
| 2025-10-07 | −43.5% | −44.1% | +3.9% |
| 2025-10-08 | −41.7% | −44.4% | +3.5% |
| 3 best | |||
| 2022-11-25 | +66.1% | +0.0% | +66.1% |
| 2022-07-15 | +65.3% | +0.0% | +65.3% |
| 2022-11-23 | +65.0% | −0.2% | +65.0% |
1,022 overlapping windows · 2022-06-16 – 2026-08-13 · not cherry-picked
Pending catalysts
- July 2027 — Trial primary completion: Phase 3 primary completion: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~5 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.